These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2188 related articles for article (PubMed ID: 27022037)

  • 1. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
    Moore KN; Monk BJ
    Oncologist; 2016 Aug; 21(8):954-63. PubMed ID: 27256873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
    Liu JF; Matulonis UA
    Curr Oncol Rep; 2016 May; 18(5):29. PubMed ID: 26984416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
    Miller RE; Ledermann JA
    Clin Adv Hematol Oncol; 2016 Sep; 14(9):704-11. PubMed ID: 27673289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.
    Lorusso D; Tripodi E; Maltese G; Lepori S; Sabatucci I; Bogani G; Raspagliesi F
    Drug Des Devel Ther; 2018; 12():1501-1509. PubMed ID: 29881257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.
    Lheureux S; Bruce JP; Burnier JV; Karakasis K; Shaw PA; Clarke BA; Yang SY; Quevedo R; Li T; Dowar M; Bowering V; Pugh TJ; Oza AM
    J Clin Oncol; 2017 Apr; 35(11):1240-1249. PubMed ID: 28221868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporating PARP-inhibitors into clinical routine: A tailored treatment strategy to tackle ovarian cancer.
    De Jaeghere E; Vandecasteele K; Claes K; Makar A; Tummers P; Cocquyt V; Denys H
    Acta Clin Belg; 2017 Feb; 72(1):6-11. PubMed ID: 27267353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
    Gunderson CC; Moore KN
    Future Oncol; 2015; 11(5):747-57. PubMed ID: 25757679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
    Miller RE; Ledermann JA
    Clin Adv Hematol Oncol; 2016 Aug; 14(8):619-27. PubMed ID: 27487106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The current status of PARP inhibitors in ovarian cancer.
    McLachlan J; George A; Banerjee S
    Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
    Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting.
    Dziadkowiec KN; Gąsiorowska E; Nowak-Markwitz E; Jankowska A
    Prz Menopauzalny; 2016 Dec; 15(4):215-219. PubMed ID: 28250726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
    Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
    Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP inhibitors in ovarian cancer: current status and future promise.
    Liu JF; Konstantinopoulos PA; Matulonis UA
    Gynecol Oncol; 2014 May; 133(2):362-9. PubMed ID: 24607283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.
    Tewari KS; Eskander RN; Monk BJ
    Clin Cancer Res; 2015 Sep; 21(17):3829-35. PubMed ID: 26169965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP inhibitors in ovarian cancer.
    Ledermann JA
    Ann Oncol; 2016 Apr; 27 Suppl 1():i40-i44. PubMed ID: 27141070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
    Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC
    Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 110.